Goldman Upgrades CIB to Buy as Stock Clears Its Own Price Target
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
CIB heads into its August 3 earnings report having done something rare: it outran the analysts covering it.
The standout development is Goldman Sachs. On July 28, Tito Labarta upgraded CIB to Buy and lifted the price target to $98 from $81 — a move that arrived just as the stock was already trading through the prior $81 target. The stock closed Thursday at $93.89, up 5% on the day and 8% on the week. Over the past month it has climbed 18%. The Goldman upgrade is the clearest signal that the Street is reassessing a name that has consistently traded ahead of consensus expectations. Other firms have been moving in the same direction: B of A lifted the stock to Neutral in June, JPMorgan raised its target in May, and UBS added $20 to its target in April. The directional drift from analysts has been unambiguously upward since the start of the year.
The bull case rests on momentum. Valuation has re-rated with the price — the price-to-book multiple has expanded by roughly 0.2x over the past 30 days to 1.88x, and the P/E now runs near 8.8x. For a Colombian diversified bank growing revenue at a double-digit pace, that remains a modest multiple. Bears, however, note that the mean consensus price target across all analysts still sits near $72 — well below the current price — suggesting many on the Street have not yet followed Goldman's lead. The most recent earnings print, in February, saw the stock fall 7.6% on the day and nearly 18% over the following five days. That print is a reminder that positive momentum alone does not insulate the stock from a disappointing result.
Options positioning has eased since the defensive spike flagged in our earlier coverage. The put/call ratio closed Wednesday at 0.43, almost exactly in line with its 20-day average of 0.43 and a z-score near zero. The hedging that was visible on July 20 — when the PCR briefly hit 0.65, more than three standard deviations above trend — has unwound. That normalisation likely reflects the stock's continued rally absorbing some of the event anxiety. Short interest reinforces the picture of a largely uncrowded trade: roughly 471,000 shares short, down more than 40% from a month ago, with borrow availability effectively unlimited and cost to borrow running below 0.5%. There is no meaningful short-side pressure in this setup.
The August 3 print will therefore test whether the fundamental delivery — loan growth, net interest margin, credit quality — can justify a stock that has moved sharply past where most analysts told clients to sell.
Stocks in this article
See the live data behind this article on ORTEX.
Open CIB on ORTEX →How this article was generated
- Generated
- 31 Jul 2026, 04:01
- Data as of
- 31 Jul 2026, 04:00
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesPrevious Mi Articles
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.